[Latar Belakang : Sesak napas merupakan keluhan utama pada kanker paru. Obatgolongan opioid seperti morfin dapat digunakan untuk mengurangi keluhan sesaknapas. Penelitian ini bertujuan untuk menetapkan efek pengurangan sesak napasdengan pemberian morfin oral lepas lambat 2x10 mg dan 2x30 mg, serta efeksamping yang ditimbulkan. Metode : Penelitian uji klinis dengan subjek pasien kanker paru denganmembandingkan keluhan sesak napas sebelum dan sesudah pemberian morfin oral2x10 mg selama 2 hari dan dilanjutkan dengan 2x30 mg selama 2 hari. Derajatsesak dinilai dengan menggunakan skor sesak modified Borg?s dyspnea scale danVisual Analog Scale (VAS) untuk sesak. Efek samping dipantau selamapemberian obat. Hasil : Tiga puluh tiga peserta penelitian dengan 27 laki-laki (81,8%), jeniskanker paru adenokarsinoma 25 orang (75,8%). Terdapat perbaikan keluhan sesaknapas setelah morfin 2x10 mg pada 18 dari 33 peserta (54,5%) dengan penurunanrata-rata skor sesak Borg dan VAS sebanyak 0,70 dan 6,72 dengan p <0,001dibanding skor awal. Setelah pemberian morfin 2x30 mg perbaikan sesak napasdidapat pada 26 dari 33 peserta (78,8%) dengan penurunan rata-rata skor sesakBorg dan VAS sebanyak 1,64 dan 16,06 dengan p <0,001 dibanding skor awal.Terdapat perbedaan bermakna antara pemberian morfin 2x10 mg dan 2x30 mg (p<0,001). Efek samping yang didapat setelah morfin 2x30 mg yaitu 33,3%mengeluh konstipasi, 42,4% mengantuk, dan 12,1% mual. Tidak ada pasien yangmengalami depresi pernapasan berat. Kesimpulan : Terdapat perbaikan keluhan sesak napas setelah pemberian morfinoral lepas lambat 2x10 mg dan dan perbaikan yang lebih baik dengan 2x30 mg. Tidak ada efek samping yang berat setelah pemberian morfin oral.;Background: Dyspnea is a major complaint in lung cancer. Opioids drugs such as morphine is known to be used to reduce dyspnea. This study aims to determinewhether there is an improvement of dyspnea by titrating morphine sustainedrelease tablet 2x10 mg and 2x30 mg in lung cancer patient, and the side effectsthat appear. Methods: The study is a clinical trial with the subject of lung cancer patients bycomparing dyspnea before and after administration of 2x10 mg morphine tabletsfor 2 days, followed by 2x30 mg for 2 days. The degree of dyspnea assessed usingthe modified Borg's dyspnea scale and the Visual Analog Scale (VAS) fordyspnea. Side effects are observed during administration of the drug. Results: Thirty-three study participants with predominantly 27 men (81.8%) and25 participants with adenocarcinoma (75.8%). There were improvements indyspnea after morphine 2x10 mg in 18 of the 33 participants (54.5%) with anaverage improvements of Borg and VAS scores for 0.70 and 6.72 with p <0.001compared to the initial score. After administration of morphine 2x30 mgimprovements in dyspnea were obtained in 26 of the 33 participants (78.8%) withan average improvements of Borg and VAS scores for 1.64 and 16.06 with p<0.001 compared to the initial score. There were significant differences betweenthe administration of morphine 2x10 mg and 2x30 mg (p <0.001). Side effectswere obtained after 2x30 mg morphine such as 33.3% complained of constipation,drowsiness in 42.4%, and nausea in 12.1%. No patients experienced severerespiratory depression. Conclusion: There is dyspnea improvement after administration of sustainedreleasemorphine tablet 2x10 mg and better improvement with 2x30 mg. No severe side effects after administration of oral morphine., Background: Dyspnea is a major complaint in lung cancer. Opioids drugs such as morphine is known to be used to reduce dyspnea. This study aims to determinewhether there is an improvement of dyspnea by titrating morphine sustainedrelease tablet 2x10 mg and 2x30 mg in lung cancer patient, and the side effectsthat appear. Methods: The study is a clinical trial with the subject of lung cancer patients bycomparing dyspnea before and after administration of 2x10 mg morphine tabletsfor 2 days, followed by 2x30 mg for 2 days. The degree of dyspnea assessed usingthe modified Borg's dyspnea scale and the Visual Analog Scale (VAS) fordyspnea. Side effects are observed during administration of the drug. Results: Thirty-three study participants with predominantly 27 men (81.8%) and25 participants with adenocarcinoma (75.8%). There were improvements indyspnea after morphine 2x10 mg in 18 of the 33 participants (54.5%) with anaverage improvements of Borg and VAS scores for 0.70 and 6.72 with p <0.001compared to the initial score. After administration of morphine 2x30 mgimprovements in dyspnea were obtained in 26 of the 33 participants (78.8%) withan average improvements of Borg and VAS scores for 1.64 and 16.06 with p<0.001 compared to the initial score. There were significant differences betweenthe administration of morphine 2x10 mg and 2x30 mg (p <0.001). Side effectswere obtained after 2x30 mg morphine such as 33.3% complained of constipation,drowsiness in 42.4%, and nausea in 12.1%. No patients experienced severerespiratory depression. Conclusion: There is dyspnea improvement after administration of sustainedreleasemorphine tablet 2x10 mg and better improvement with 2x30 mg. No severe side effects after administration of oral morphine.] |